

Blood Plasma Derivatives Market Forecasts to 2032 – Global Analysis By Type (Albumin, Factor VIII, Factor IX, Immunoglobulin, Hyperimmune Globulin and Other Types), Process (Cold Ethanol Fractionation, Heat Treatment and Chromatography), Application, End User and By Geography

<https://marketpublishers.com/r/BC7B363DD7FDEN.html>

Date: April 2025

Pages: 150

Price: US\$ 4,150.00 (Single User License)

ID: BC7B363DD7FDEN

Abstracts

According to Statistics MRC, the Global Blood Plasma Derivatives Market is accounted for \$56.71 billion in 2025 and is expected to reach \$115.52 billion by 2032 growing at a CAGR of 10.7% during the forecast period. Human plasma, the liquid component of blood, is the source of specialized medicinal products known as blood plasma derivatives. Essential proteins like albumin, immunoglobulins, clotting factors, and alpha-1 antitrypsin are among these derivatives and are frequently used to treat a variety of illnesses. Immunodeficiencies, hemophilia, and neurological conditions like Guillain-Barre syndrome are all treated with their help. Fractionation, a technique used to isolate and purify particular proteins for medical applications, yields plasma derivatives.

According to the World Federation of Hemophilia (WFH), hemophilia affects approximately 1 in 10,000 people globally.

Market Dynamics:

Driver:

Increasing number of elderly people

A major factor in the rising demand for therapies derived from plasma is the aging population. The elderly are significant users of plasma derivatives because they are more susceptible to diseases like coagulation problems, chronic liver disease, and immunological deficiencies. Approximately 1.6 billion people, or one in six people worldwide, will be over 65 by 2050, according to UN estimates. Additionally, the risk of infections, cardiovascular conditions, and autoimmune diseases increases with age; many of these conditions are treated with plasma proteins such as albumin and immunoglobulins.

Restraint:

Exorbitant expenses for production and processing

The complicated and time-consuming plasma fractionation process makes the production of therapies derived from plasma extremely costly. Plasma collection and final product release can take seven to twelve months, which results in high operating costs. For plasma proteins to remain stable and effective, plasma fractionation necessitates specialized equipment, rigorous quality control testing, and a sizable storage infrastructure. Furthermore, the total cost of production is raised by the requirement for several liters of plasma to generate a small amount of the finished product. For instance, to make enough Intravenous Immunoglobulin (IVIG) to treat one patient for a year, about 130 plasma donations are needed.

Opportunity:

Growing interest in immunoglobulin and plasma treatments

Intravenous immunoglobulins (IVIG) and subcutaneous immunoglobulins (SCIG) are in high demand due to the increasing incidence of immune deficiencies, neurological conditions, and autoimmune diseases. Long-term immunoglobulin therapy is necessary for conditions like Kawasaki disease, chronic inflammatory demyelinating polyneuropathy (CIDP), and primary immunodeficiency disorders (PID). Industry estimates indicate that the demand for IVIG has been rising globally at a rate of more than 8% per year, which has created significant growth prospects for the market. Moreover, prospects for the market are further enhanced by the extension of plasma-derived immunoglobulin treatment indications into conditions like sepsis, multiple sclerosis, and Alzheimer's disease.

Threat:

Lack of plasma donations and limitations on supply

The worldwide supply of plasma is largely reliant on donor participation, which varies depending on socioeconomic factors, regulatory limitations, and public attitudes regarding plasma donation. Policy changes and donor compensation ethical discussions could cause disruptions for nations like the US that depend on compensated plasma donation models. Additionally, the COVID-19 pandemic brought to light the vulnerability of plasma collection, as notable drops in donations resulted in immunoglobulin and clotting factor shortages.

Covid-19 Impact:

The COVID-19 pandemic had a major effect on the market for blood plasma derivatives because it caused delays in manufacturing, disruptions in plasma collection, and an increase in demand for immunoglobulins. Lockdowns and social distancing policies caused plasma donations to drop, particularly in important markets like the US and Europe, which resulted in a shortage of vital therapies derived from plasma. Furthermore, the supply chain for other plasma-derived products was also impacted by the brief shift in industry focus caused by the explosion in research on convalescent plasma therapy for COVID-19 patients.

The Immunoglobulin segment is expected to be the largest during the forecast period

The Immunoglobulin segment is expected to account for the largest market share during the forecast period, motivated by its extensive application in the treatment of autoimmune diseases, primary and secondary immunodeficiency's, and neurological disorders like Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy (CIDP). The demand for immunoglobulin products has been driven by the growing number of elderly people, the increasing prevalence of immunodeficiency diseases, and the growing knowledge of plasma-derived treatments. Furthermore, improvements in immunoglobulin formulations for intravenous (IVIG) and subcutaneous (SCIG) administration have enhanced patient convenience and treatment compliance.

The Chromatography segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Chromatography segment is predicted to witness the highest growth rate, motivated by its exceptional efficiency, purity, and precision in

plasma protein separation. Chromatography is becoming more and more popular for producing immunoglobulins, albumin, and coagulation factors because it provides superior yield and specificity compared to conventional techniques like cold ethanol fractionation. Its quick adoption is being fueled by the rising demand for high-purity plasma-derived treatments, improvements in affinity and ion-exchange chromatography, and rising investments in biopharmaceutical research. Moreover, the market growth of chromatography-based purification is further enhanced by regulatory bodies' preference for it because of its superior pathogen removal capabilities.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, driven by a robust presence of major market players, high plasma donation rates, and sophisticated healthcare infrastructure. Because of its well-established plasma donation facilities and advantageous reimbursement policies, the United States leads the region and contributes significantly to global plasma collection. The market is growing due to the rising incidence of neurological diseases, hemophilia, and immune disorders, as well as increased awareness of therapies derived from plasma. Additionally, North America's dominant market position is also a result of the FDA's strong regulatory support, continuous research into plasma fractionation technologies, and widespread use of immunoglobulin treatments.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by the growing prevalence of immunodeficiency disorders, growing awareness of plasma-derived therapies, and rising healthcare costs. Government support for biologics and plasma fractionation, growing plasma collection programs, and better healthcare infrastructure are all contributing to the rapid expansion of nations like China, India, and Japan. The market is growing as a result of rising demand for coagulation factors and immunoglobulins, as well as investments in sophisticated purification technologies and growing pharmaceutical manufacturing capacities.

Key players in the market

Some of the key players in Blood Plasma Derivatives Market include Bayer AG, Fusion Health Care Pvt. Ltd., Grifols, S.A., Takeda Pharmaceutical Company, Sanofi, CSL Limited, LFB S.A., Baxter International Inc., Syntegon, Green Cross Corporation, Octapharma AG, Biotest AG, Kedrion Biopharma, Inc., SK Plasma Co., Ltd. and Intas

Pharmaceuticals Ltd.

Key Developments:

In February 2025, Sanofi and CD&R have signed the share purchase agreement for the sale of a 50% controlling stake in its consumer health business Opella to US private equity firm Clayton Dubilier & Rice (CD&R). The terms of the transaction remain unchanged from those previously announced and closing is expected in the second quarter of 2025 at the earliest.

In January 2025, Bayer announced that the company has signed a new exclusive distribution agreement with UK-based Ecospray to market a biological liquid nematicide sourced from garlic. The product presents a biological alternative to traditional synthetic chemical nematicides in vegetable and potato crops, and will be marketed in the European Union under the new name Velsinum™.

In June 2024, Takeda announced the signing of an option agreement with Ascentage Pharma to enter into an exclusive license agreement for olverembatinib, an oral, potentially best-in-class, third-generation BCR-ABL tyrosine kinase inhibitor (TKI), which is currently in development for chronic myeloid leukemia (CML) and other hematological cancers.

Types Covered:

Albumin

Factor VIII

Factor IX

Immunoglobulin

Hyperimmune Globulin

Other Types

Processes Covered:

Cold Ethanol Fractionation

Heat Treatment

Chromatography

Applications Covered:

Hemophilia

Hypogammaglobulinemia

Immunodeficiency Diseases

Von Willebrand'S Disease

Other Applications

End Users Covered:

Hospitals

Clinics

Other End Users

Regions Covered:

North America

US

Canada

Mexico

Europe

Germany

UK

Italy

France

Spain

Rest of Europe

Asia Pacific

Japan

China

India

Australia

New Zealand

South Korea

Rest of Asia Pacific

South America

Argentina

Brazil

Chile

Rest of South America

Middle East & Africa

Saudi Arabia

UAE

Qatar

South Africa

Rest of Middle East & Africa

What our report offers:

- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling

Comprehensive profiling of additional market players (up to 3)

SWOT Analysis of key players (up to 3)

Regional Segmentation

Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)

Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Contents

1 EXECUTIVE SUMMARY

2 PREFACE

- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
 - 2.4.1 Data Mining
 - 2.4.2 Data Analysis
 - 2.4.3 Data Validation
 - 2.4.4 Research Approach
- 2.5 Research Sources
 - 2.5.1 Primary Research Sources
 - 2.5.2 Secondary Research Sources
 - 2.5.3 Assumptions

3 MARKET TREND ANALYSIS

- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 Application Analysis
- 3.7 End User Analysis
- 3.8 Emerging Markets
- 3.9 Impact of Covid-19

4 PORTERS FIVE FORCE ANALYSIS

- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry

5 GLOBAL BLOOD PLASMA DERIVATIVES MARKET, BY TYPE

- 5.1 Introduction
- 5.2 Albumin
- 5.3 Factor VIII
- 5.4 Factor IX
- 5.5 Immunoglobulin
- 5.6 Hyperimmune Globulin
- 5.7 Other Types

6 GLOBAL BLOOD PLASMA DERIVATIVES MARKET, BY PROCESS

- 6.1 Introduction
- 6.2 Cold Ethanol Fractionation
- 6.3 Heat Treatment
- 6.4 Chromatography

7 GLOBAL BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION

- 7.1 Introduction
- 7.2 Hemophilia
- 7.3 Hypogammaglobulinemia
- 7.4 Immunodeficiency Diseases
- 7.5 Von Willebrand'S Disease
- 7.6 Other Applications

8 GLOBAL BLOOD PLASMA DERIVATIVES MARKET, BY END USER

- 8.1 Introduction
- 8.2 Hospitals
- 8.3 Clinics
- 8.4 Other End Users

9 GLOBAL BLOOD PLASMA DERIVATIVES MARKET, BY GEOGRAPHY

- 9.1 Introduction
- 9.2 North America
 - 9.2.1 US
 - 9.2.2 Canada

- 9.2.3 Mexico
- 9.3 Europe
 - 9.3.1 Germany
 - 9.3.2 UK
 - 9.3.3 Italy
 - 9.3.4 France
 - 9.3.5 Spain
 - 9.3.6 Rest of Europe
- 9.4 Asia Pacific
 - 9.4.1 Japan
 - 9.4.2 China
 - 9.4.3 India
 - 9.4.4 Australia
 - 9.4.5 New Zealand
 - 9.4.6 South Korea
 - 9.4.7 Rest of Asia Pacific
- 9.5 South America
 - 9.5.1 Argentina
 - 9.5.2 Brazil
 - 9.5.3 Chile
 - 9.5.4 Rest of South America
- 9.6 Middle East & Africa
 - 9.6.1 Saudi Arabia
 - 9.6.2 UAE
 - 9.6.3 Qatar
 - 9.6.4 South Africa
 - 9.6.5 Rest of Middle East & Africa

10 KEY DEVELOPMENTS

- 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 10.2 Acquisitions & Mergers
- 10.3 New Product Launch
- 10.4 Expansions
- 10.5 Other Key Strategies

11 COMPANY PROFILING

- 11.1 Bayer AG

- 11.2 Fusion Health Care Pvt. Ltd.
- 11.3 Grifols, S.A.
- 11.4 Takeda Pharmaceutical Company
- 11.5 Sanofi
- 11.6 CSL Limited
- 11.7 LFB S.A.
- 11.8 Baxter International Inc.
- 11.9 Syntegon
- 11.10 Green Cross Corporation
- 11.11 Octapharma AG
- 11.12 Biotest AG
- 11.13 Kedrion Biopharma, Inc.
- 11.14 SK Plasma Co., Ltd.
- 11.15 Intas Pharmaceuticals Ltd.

List Of Tables

LIST OF TABLES

Table 1 Global Blood Plasma Derivatives Market Outlook, By Region (2024-2032) (\$MN)

Table 2 Global Blood Plasma Derivatives Market Outlook, By Type (2024-2032) (\$MN)

Table 3 Global Blood Plasma Derivatives Market Outlook, By Albumin (2024-2032) (\$MN)

Table 4 Global Blood Plasma Derivatives Market Outlook, By Factor VIII (2024-2032) (\$MN)

Table 5 Global Blood Plasma Derivatives Market Outlook, By Factor IX (2024-2032) (\$MN)

Table 6 Global Blood Plasma Derivatives Market Outlook, By Immunoglobulin (2024-2032) (\$MN)

Table 7 Global Blood Plasma Derivatives Market Outlook, By Hyperimmune Globulin (2024-2032) (\$MN)

Table 8 Global Blood Plasma Derivatives Market Outlook, By Other Types (2024-2032) (\$MN)

Table 9 Global Blood Plasma Derivatives Market Outlook, By Process (2024-2032) (\$MN)

Table 10 Global Blood Plasma Derivatives Market Outlook, By Cold Ethanol Fractionation (2024-2032) (\$MN)

Table 11 Global Blood Plasma Derivatives Market Outlook, By Heat Treatment (2024-2032) (\$MN)

Table 12 Global Blood Plasma Derivatives Market Outlook, By Chromatography (2024-2032) (\$MN)

Table 13 Global Blood Plasma Derivatives Market Outlook, By Application (2024-2032) (\$MN)

Table 14 Global Blood Plasma Derivatives Market Outlook, By Hemophilia (2024-2032) (\$MN)

Table 15 Global Blood Plasma Derivatives Market Outlook, By Hypogammaglobulinemia (2024-2032) (\$MN)

Table 16 Global Blood Plasma Derivatives Market Outlook, By Immunodeficiency Diseases (2024-2032) (\$MN)

Table 17 Global Blood Plasma Derivatives Market Outlook, By Von Willebrand'S Disease (2024-2032) (\$MN)

Table 18 Global Blood Plasma Derivatives Market Outlook, By Other Applications (2024-2032) (\$MN)

Table 19 Global Blood Plasma Derivatives Market Outlook, By End User (2024-2032) (\$MN)

Table 20 Global Blood Plasma Derivatives Market Outlook, By Hospitals (2024-2032) (\$MN)

Table 21 Global Blood Plasma Derivatives Market Outlook, By Clinics (2024-2032) (\$MN)

Table 22 Global Blood Plasma Derivatives Market Outlook, By Other End Users (2024-2032) (\$MN)

Table 23 North America Blood Plasma Derivatives Market Outlook, By Country (2024-2032) (\$MN)

Table 24 North America Blood Plasma Derivatives Market Outlook, By Type (2024-2032) (\$MN)

Table 25 North America Blood Plasma Derivatives Market Outlook, By Albumin (2024-2032) (\$MN)

Table 26 North America Blood Plasma Derivatives Market Outlook, By Factor VIII (2024-2032) (\$MN)

Table 27 North America Blood Plasma Derivatives Market Outlook, By Factor IX (2024-2032) (\$MN)

Table 28 North America Blood Plasma Derivatives Market Outlook, By Immunoglobulin (2024-2032) (\$MN)

Table 29 North America Blood Plasma Derivatives Market Outlook, By Hyperimmune Globulin (2024-2032) (\$MN)

Table 30 North America Blood Plasma Derivatives Market Outlook, By Other Types (2024-2032) (\$MN)

Table 31 North America Blood Plasma Derivatives Market Outlook, By Process (2024-2032) (\$MN)

Table 32 North America Blood Plasma Derivatives Market Outlook, By Cold Ethanol Fractionation (2024-2032) (\$MN)

Table 33 North America Blood Plasma Derivatives Market Outlook, By Heat Treatment (2024-2032) (\$MN)

Table 34 North America Blood Plasma Derivatives Market Outlook, By Chromatography (2024-2032) (\$MN)

Table 35 North America Blood Plasma Derivatives Market Outlook, By Application (2024-2032) (\$MN)

Table 36 North America Blood Plasma Derivatives Market Outlook, By Hemophilia (2024-2032) (\$MN)

Table 37 North America Blood Plasma Derivatives Market Outlook, By Hypogammaglobulinemia (2024-2032) (\$MN)

Table 38 North America Blood Plasma Derivatives Market Outlook, By

Immunodeficiency Diseases (2024-2032) (\$MN)

Table 39 North America Blood Plasma Derivatives Market Outlook, By Von Willebrand'S Disease (2024-2032) (\$MN)

Table 40 North America Blood Plasma Derivatives Market Outlook, By Other Applications (2024-2032) (\$MN)

Table 41 North America Blood Plasma Derivatives Market Outlook, By End User (2024-2032) (\$MN)

Table 42 North America Blood Plasma Derivatives Market Outlook, By Hospitals (2024-2032) (\$MN)

Table 43 North America Blood Plasma Derivatives Market Outlook, By Clinics (2024-2032) (\$MN)

Table 44 North America Blood Plasma Derivatives Market Outlook, By Other End Users (2024-2032) (\$MN)

Table 45 Europe Blood Plasma Derivatives Market Outlook, By Country (2024-2032) (\$MN)

Table 46 Europe Blood Plasma Derivatives Market Outlook, By Type (2024-2032) (\$MN)

Table 47 Europe Blood Plasma Derivatives Market Outlook, By Albumin (2024-2032) (\$MN)

Table 48 Europe Blood Plasma Derivatives Market Outlook, By Factor VIII (2024-2032) (\$MN)

Table 49 Europe Blood Plasma Derivatives Market Outlook, By Factor IX (2024-2032) (\$MN)

Table 50 Europe Blood Plasma Derivatives Market Outlook, By Immunoglobulin (2024-2032) (\$MN)

Table 51 Europe Blood Plasma Derivatives Market Outlook, By Hyperimmune Globulin (2024-2032) (\$MN)

Table 52 Europe Blood Plasma Derivatives Market Outlook, By Other Types (2024-2032) (\$MN)

Table 53 Europe Blood Plasma Derivatives Market Outlook, By Process (2024-2032) (\$MN)

Table 54 Europe Blood Plasma Derivatives Market Outlook, By Cold Ethanol Fractionation (2024-2032) (\$MN)

Table 55 Europe Blood Plasma Derivatives Market Outlook, By Heat Treatment (2024-2032) (\$MN)

Table 56 Europe Blood Plasma Derivatives Market Outlook, By Chromatography (2024-2032) (\$MN)

Table 57 Europe Blood Plasma Derivatives Market Outlook, By Application (2024-2032) (\$MN)

Table 58 Europe Blood Plasma Derivatives Market Outlook, By Hemophilia (2024-2032) (\$MN)

Table 59 Europe Blood Plasma Derivatives Market Outlook, By Hypogammaglobulinemia (2024-2032) (\$MN)

Table 60 Europe Blood Plasma Derivatives Market Outlook, By Immunodeficiency Diseases (2024-2032) (\$MN)

Table 61 Europe Blood Plasma Derivatives Market Outlook, By Von Willebrand'S Disease (2024-2032) (\$MN)

Table 62 Europe Blood Plasma Derivatives Market Outlook, By Other Applications (2024-2032) (\$MN)

Table 63 Europe Blood Plasma Derivatives Market Outlook, By End User (2024-2032) (\$MN)

Table 64 Europe Blood Plasma Derivatives Market Outlook, By Hospitals (2024-2032) (\$MN)

Table 65 Europe Blood Plasma Derivatives Market Outlook, By Clinics (2024-2032) (\$MN)

Table 66 Europe Blood Plasma Derivatives Market Outlook, By Other End Users (2024-2032) (\$MN)

Table 67 Asia Pacific Blood Plasma Derivatives Market Outlook, By Country (2024-2032) (\$MN)

Table 68 Asia Pacific Blood Plasma Derivatives Market Outlook, By Type (2024-2032) (\$MN)

Table 69 Asia Pacific Blood Plasma Derivatives Market Outlook, By Albumin (2024-2032) (\$MN)

Table 70 Asia Pacific Blood Plasma Derivatives Market Outlook, By Factor VIII (2024-2032) (\$MN)

Table 71 Asia Pacific Blood Plasma Derivatives Market Outlook, By Factor IX (2024-2032) (\$MN)

Table 72 Asia Pacific Blood Plasma Derivatives Market Outlook, By Immunoglobulin (2024-2032) (\$MN)

Table 73 Asia Pacific Blood Plasma Derivatives Market Outlook, By Hyperimmune Globulin (2024-2032) (\$MN)

Table 74 Asia Pacific Blood Plasma Derivatives Market Outlook, By Other Types (2024-2032) (\$MN)

Table 75 Asia Pacific Blood Plasma Derivatives Market Outlook, By Process (2024-2032) (\$MN)

Table 76 Asia Pacific Blood Plasma Derivatives Market Outlook, By Cold Ethanol Fractionation (2024-2032) (\$MN)

Table 77 Asia Pacific Blood Plasma Derivatives Market Outlook, By Heat Treatment

(2024-2032) (\$MN)

Table 78 Asia Pacific Blood Plasma Derivatives Market Outlook, By Chromatography (2024-2032) (\$MN)

Table 79 Asia Pacific Blood Plasma Derivatives Market Outlook, By Application (2024-2032) (\$MN)

Table 80 Asia Pacific Blood Plasma Derivatives Market Outlook, By Hemophilia (2024-2032) (\$MN)

Table 81 Asia Pacific Blood Plasma Derivatives Market Outlook, By Hypogammaglobulinemia (2024-2032) (\$MN)

Table 82 Asia Pacific Blood Plasma Derivatives Market Outlook, By Immunodeficiency Diseases (2024-2032) (\$MN)

Table 83 Asia Pacific Blood Plasma Derivatives Market Outlook, By Von Willebrand'S Disease (2024-2032) (\$MN)

Table 84 Asia Pacific Blood Plasma Derivatives Market Outlook, By Other Applications (2024-2032) (\$MN)

Table 85 Asia Pacific Blood Plasma Derivatives Market Outlook, By End User (2024-2032) (\$MN)

Table 86 Asia Pacific Blood Plasma Derivatives Market Outlook, By Hospitals (2024-2032) (\$MN)

Table 87 Asia Pacific Blood Plasma Derivatives Market Outlook, By Clinics (2024-2032) (\$MN)

Table 88 Asia Pacific Blood Plasma Derivatives Market Outlook, By Other End Users (2024-2032) (\$MN)

Table 89 South America Blood Plasma Derivatives Market Outlook, By Country (2024-2032) (\$MN)

Table 90 South America Blood Plasma Derivatives Market Outlook, By Type (2024-2032) (\$MN)

Table 91 South America Blood Plasma Derivatives Market Outlook, By Albumin (2024-2032) (\$MN)

Table 92 South America Blood Plasma Derivatives Market Outlook, By Factor VIII (2024-2032) (\$MN)

Table 93 South America Blood Plasma Derivatives Market Outlook, By Factor IX (2024-2032) (\$MN)

Table 94 South America Blood Plasma Derivatives Market Outlook, By Immunoglobulin (2024-2032) (\$MN)

Table 95 South America Blood Plasma Derivatives Market Outlook, By Hyperimmune Globulin (2024-2032) (\$MN)

Table 96 South America Blood Plasma Derivatives Market Outlook, By Other Types (2024-2032) (\$MN)

Table 97 South America Blood Plasma Derivatives Market Outlook, By Process (2024-2032) (\$MN)

Table 98 South America Blood Plasma Derivatives Market Outlook, By Cold Ethanol Fractionation (2024-2032) (\$MN)

Table 99 South America Blood Plasma Derivatives Market Outlook, By Heat Treatment (2024-2032) (\$MN)

Table 100 South America Blood Plasma Derivatives Market Outlook, By Chromatography (2024-2032) (\$MN)

Table 101 South America Blood Plasma Derivatives Market Outlook, By Application (2024-2032) (\$MN)

Table 102 South America Blood Plasma Derivatives Market Outlook, By Hemophilia (2024-2032) (\$MN)

Table 103 South America Blood Plasma Derivatives Market Outlook, By Hypogammaglobulinemia (2024-2032) (\$MN)

Table 104 South America Blood Plasma Derivatives Market Outlook, By Immunodeficiency Diseases (2024-2032) (\$MN)

Table 105 South America Blood Plasma Derivatives Market Outlook, By Von Willebrand'S Disease (2024-2032) (\$MN)

Table 106 South America Blood Plasma Derivatives Market Outlook, By Other Applications (2024-2032) (\$MN)

Table 107 South America Blood Plasma Derivatives Market Outlook, By End User (2024-2032) (\$MN)

Table 108 South America Blood Plasma Derivatives Market Outlook, By Hospitals (2024-2032) (\$MN)

Table 109 South America Blood Plasma Derivatives Market Outlook, By Clinics (2024-2032) (\$MN)

Table 110 South America Blood Plasma Derivatives Market Outlook, By Other End Users (2024-2032) (\$MN)

Table 111 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Country (2024-2032) (\$MN)

Table 112 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Type (2024-2032) (\$MN)

Table 113 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Albumin (2024-2032) (\$MN)

Table 114 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Factor VIII (2024-2032) (\$MN)

Table 115 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Factor IX (2024-2032) (\$MN)

Table 116 Middle East & Africa Blood Plasma Derivatives Market Outlook, By

Immunoglobulin (2024-2032) (\$MN)

Table 117 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Hyperimmune Globulin (2024-2032) (\$MN)

Table 118 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Other Types (2024-2032) (\$MN)

Table 119 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Process (2024-2032) (\$MN)

Table 120 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Cold Ethanol Fractionation (2024-2032) (\$MN)

Table 121 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Heat Treatment (2024-2032) (\$MN)

Table 122 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Chromatography (2024-2032) (\$MN)

Table 123 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Application (2024-2032) (\$MN)

Table 124 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Hemophilia (2024-2032) (\$MN)

Table 125 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Hypogammaglobulinemia (2024-2032) (\$MN)

Table 126 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Immunodeficiency Diseases (2024-2032) (\$MN)

Table 127 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Von Willebrand'S Disease (2024-2032) (\$MN)

Table 128 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Other Applications (2024-2032) (\$MN)

Table 129 Middle East & Africa Blood Plasma Derivatives Market Outlook, By End User (2024-2032) (\$MN)

Table 130 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Hospitals (2024-2032) (\$MN)

Table 131 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Clinics (2024-2032) (\$MN)

Table 132 Middle East & Africa Blood Plasma Derivatives Market Outlook, By Other End Users (2024-2032) (\$MN)

I would like to order

Product name: Blood Plasma Derivatives Market Forecasts to 2032 – Global Analysis By Type (Albumin, Factor VIII, Factor IX, Immunoglobulin, Hyperimmune Globulin and Other Types), Process (Cold Ethanol Fractionation, Heat Treatment and Chromatography), Application, End User and By Geography

Product link: <https://marketpublishers.com/r/BC7B363DD7FDEN.html>

Price: US\$ 4,150.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BC7B363DD7FDEN.html>